Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

carboplatin/paclitaxel regimen

View Patient Information
A regimen consisting of carboplatin and paclitaxel that may be used for the treatment of breast, kidney, cervical, vulvar, endometrial, ovarian, fallopian tube, primary peritoneal, head and neck, including cancer of the nasopharynx, esophageal and esophagogastric junction, and gastric cancers; non-small cell lung cancer (NSCLC); anaplastic carcinoma; anal, small bowel and non-urothelial and urothelial bladder cancer; salivary gland, malignant germ cell and malignant sex cord-stromal tumors; cutaneous and uveal melanoma; squamous cell skin cancer; thymomas and thymic carcinoma; occult primary adenocarcinoma or squamous cell carcinoma. Paclitaxel/carboplatin every 21 days regimen may be used for the treatment of esophageal and esophagogastric junction, and gastric cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:carbo-Tax regimen
carboplatin-paclitaxel
carboplatin-paclitaxel regimen
carboplatin-Taxol
carboplatin/paclitaxel
CaT regimen
paclitaxel-carboplatin
paclitaxel-carboplatin regimen
paclitaxel/carboplatin
paclitaxel/carboplatin regimen
PC regimen
TC regimen
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search